Brian Durkin - AbbVie Vice President Controller
President
Mr. Brian L. Durkin serves as Vice President, Controller of the Company. Mr. Durkin previously served as Vice President, Internal Audit from 2016 to 2018. Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbotts Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009. Mr. Durkin joined Abbott in 1986. since 2018.
| Age | 60 |
| Tenure | 7 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6229 %, meaning that it created $0.6229 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.10 in 2025. Return On Capital Employed is likely to drop to 0.09 in 2025. At this time, AbbVie's Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 9.6 B in 2025, whereas Non Current Assets Total are likely to drop slightly above 61.9 B in 2025.AbbVie Inc currently holds 67.14 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AbbVie's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Mikael Dolsten | Pfizer Inc | 62 | |
| Sally Susman | Pfizer Inc | 63 | |
| Murdo Gordon | Amgen Inc | 58 | |
| James Swanson | Johnson Johnson | 58 | |
| Jyoti Mehra | Gilead Sciences | 48 | |
| Jennifer Zachary | Merck Company | 46 | |
| Frank DAmelio | Pfizer Inc | 66 | |
| Julie Gerberding | Merck Company | 64 | |
| Dawn Rogers | Pfizer Inc | 54 | |
| Albert Bourla | Pfizer Inc | 59 | |
| Roger Perlmutter | Merck Company | 67 | |
| Andrew Dickinson | Gilead Sciences | 55 | |
| Payal Sahni | Pfizer Inc | 46 | |
| Angela Hwang | Pfizer Inc | 58 | |
| Richard DeLuca | Merck Company | 62 | |
| Peter Fasolo | Johnson Johnson | 61 | |
| Robert Davis | Merck Company | 54 | |
| Lidia Fonseca | Pfizer Inc | 56 | |
| Joseph Wolk | Johnson Johnson | 54 | |
| Franklin Clyburn | Merck Company | 56 | |
| Michael Sneed | Johnson Johnson | 60 | |
Management Performance
| Return On Equity | 0.62 | ||||
| Return On Asset | 0.0849 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Azita Gerhardt, Executive Vice President - Operations | ||
| Robert CPA, CEO Director | ||
| Carlos Alban, Vice Chairman, Chief Commercial Officer | ||
| Robert Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer | ||
| Jeffrey Stewart, Executive Vice President, Chief Commercial Officer | ||
| Carrie Strom, Senior Vice President AbbVie and President Global Allergan Aesthetics | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President - Finance and Administration | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, General VP | ||
| Azita SalekiGerhardt, Executive Vice President - Operations | ||
| Scott Reents, Executive CFO | ||
| Thomas Freyman, Independent Director | ||
| Thomas MD, Senior Research | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee | ||
| Tracie Haas, Brand Responsibility | ||
| Sanjay Narayan, Chief SVP | ||
| Brian Durkin, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Latif MD, Senior Research | ||
| Thomas Hudson, Senior Vice President Research & Development and Chief Scientific Officer | ||
| Roopal MD, Executive Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Assil Omar, VP Officer | ||
| Greg Miley, Senior Affairs | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, Senior Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Elaine Sorg, Senior Vice President U.S. Commercial Operations | ||
| WulffErik Borcke, Senior Oncology | ||
| Timothy Richmond, Chief Human Resource Officer, Executive Vice President | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Independent Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.62 | ||||
| Return On Asset | 0.0849 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 436.29 B | ||||
| Shares Outstanding | 1.77 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 74.08 % | ||||
| Number Of Shares Shorted | 18.51 M | ||||
| Price To Earning | 21.28 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Tools for AbbVie Stock
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |